Xencor, Inc. (NASDAQ:XNCR) Receives $36.56 Average PT from Analysts

Xencor, Inc. (NASDAQ:XNCR) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $36.56.

Several equities research analysts have recently commented on the company. Royal Bank of Canada boosted their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Xencor in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company began coverage on shares of Xencor in a report on Thursday, December 12th. They set an “overweight” rating and a $37.00 price objective for the company. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $20.00 to $30.00 in a report on Monday, December 2nd.

Insider Buying and Selling at Xencor

In related news, CEO Bassil I. Dahiyat sold 3,366 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total value of $80,851.32. Following the transaction, the chief executive officer now directly owns 352,615 shares of the company’s stock, valued at approximately $8,469,812.30. The trade was a 0.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the transaction, the vice president now owns 200,104 shares of the company’s stock, valued at approximately $4,698,441.92. The trade was a 25.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 136,050 shares of company stock worth $3,277,609. Insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new stake in shares of Xencor in the 2nd quarter worth approximately $154,000. Louisiana State Employees Retirement System raised its stake in shares of Xencor by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 900 shares during the period. Baillie Gifford & Co. lifted its position in shares of Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 744 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Xencor by 3.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 500,708 shares of the biopharmaceutical company’s stock worth $9,478,000 after acquiring an additional 15,974 shares during the period. Finally, Panagora Asset Management Inc. increased its holdings in Xencor by 9.4% in the 2nd quarter. Panagora Asset Management Inc. now owns 232,375 shares of the biopharmaceutical company’s stock worth $4,399,000 after acquiring an additional 20,043 shares during the last quarter.

Xencor Stock Up 0.5 %

Shares of NASDAQ XNCR opened at $24.13 on Friday. Xencor has a 12-month low of $15.31 and a 12-month high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.69 billion, a PE ratio of -7.54 and a beta of 0.69. The company’s fifty day simple moving average is $23.46 and its 200 day simple moving average is $20.68.

Xencor (NASDAQ:XNCR) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. During the same period last year, the business posted ($0.40) EPS. The firm’s revenue for the quarter was down 81.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Xencor will post -3.71 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.